TY - JOUR
T1 - Patient-derived induced pluripotent stem cells for models of cancer and cancer stem cell research
AU - Chao, Hsiao Mei
AU - Chern, Edward
N1 - Publisher Copyright:
© 2018
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Induced pluripotent stem cells (iPSCs) are embryonic stem cell-like cells reprogrammed from somatic cells by four transcription factors, OCT4, SOX2, KLF4 and c-MYC. iPSCs derived from cancer cells (cancer-iPSCs) could be a novel strategy for studying cancer. During cancer cell reprogramming, the epigenetic status of the cancer cell may be altered, such that it acquires stemness and pluripotency. The cellular behavior of the reprogrammed cells exhibits dynamic changes during the different stages of reprogramming. The cells may acquire the properties of cancer stem cells (CSCs) during the process of reprogramming, and lose their carcinogenic properties during reprogramming into a cancer-iPSCs. Differentiation of cancer-iPSCs by teratoma formation or organoid culturing could mimic the process of tumorigenesis. Some of the molecular mechanisms associated with cancer progression could be elucidated using the cancer-iPSC model. Furthermore, cancer-iPSCs could be expanded in culture system or bioreactors, and serve as cell sources for research, and as personal disease models for therapy and drug screening. This article introduces cancer studies that used the cell reprogramming strategy.
AB - Induced pluripotent stem cells (iPSCs) are embryonic stem cell-like cells reprogrammed from somatic cells by four transcription factors, OCT4, SOX2, KLF4 and c-MYC. iPSCs derived from cancer cells (cancer-iPSCs) could be a novel strategy for studying cancer. During cancer cell reprogramming, the epigenetic status of the cancer cell may be altered, such that it acquires stemness and pluripotency. The cellular behavior of the reprogrammed cells exhibits dynamic changes during the different stages of reprogramming. The cells may acquire the properties of cancer stem cells (CSCs) during the process of reprogramming, and lose their carcinogenic properties during reprogramming into a cancer-iPSCs. Differentiation of cancer-iPSCs by teratoma formation or organoid culturing could mimic the process of tumorigenesis. Some of the molecular mechanisms associated with cancer progression could be elucidated using the cancer-iPSC model. Furthermore, cancer-iPSCs could be expanded in culture system or bioreactors, and serve as cell sources for research, and as personal disease models for therapy and drug screening. This article introduces cancer studies that used the cell reprogramming strategy.
KW - Cancer stem cell
KW - Cell reprogramming
KW - Induced pluripotent stem cells (iPSCs)
KW - Tumorigenesis
UR - http://www.scopus.com/inward/record.url?scp=85054172581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054172581&partnerID=8YFLogxK
U2 - 10.1016/j.jfma.2018.06.013
DO - 10.1016/j.jfma.2018.06.013
M3 - Review article
AN - SCOPUS:85054172581
SN - 0929-6646
VL - 117
SP - 1046
EP - 1057
JO - Journal of the Formosan Medical Association
JF - Journal of the Formosan Medical Association
IS - 12
ER -